Search - tctmd.com

Displaying 121 - 140 of 555

Sort: Relevancy | Date

Presentation TCT 2022

Lifetime Management, Durability and Clinical Relevance to Patients

Presenter: John Webb

September 17, 2022

Presentation TCT 2022

Dietary and Lifestyle Approaches to Hypertension Management: What’s New and What’s Changed

Presenter: Debbie Cohen

September 17, 2022

Presentation TCT 2022

Have We Gotten to the Final Word on Paclitaxel Safety?

Presenter: Eric Secemsky

September 17, 2022

Presentation TCT 2022

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Presenter: Marc Bonaca

September 17, 2022

News Conference News TCT 2022

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

Todd Neale

September 16, 2022

News Conference News TCT 2022

Primordial Prevention Before End-stage CVD: Experts Call for a Fresh Focus

Yael L. Maxwell

September 16, 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

Shelley Wood

September 07, 2022

News Conference News TCT 2021

Mortality High in Patients With STEMI, COVID-19 on Hemodynamic Support

Caitlin E. Cox

November 11, 2021

News Conference News TCT 2021

Debating ISCHEMIA: Do the Results Apply to CABG, Too?

Michael O'Riordan

November 10, 2021

News Conference News TCT 2021

Conservative Management, Careful Diagnosis Key for Good SCAD Outcomes

Yael L. Maxwell

November 09, 2021

Presentation TCT 2021

TARGET AC 4-year Results & Deep Dive in Diabetes Subgroup

Presenter: Alexandra Lansky

November 06, 2021

News Conference News TCT 2021

GUIDE-HF Hints That Hemodynamic-Guided Management Works in HFpEF

Michael O'Riordan

November 06, 2021

Presentation TCT 2021

Establishing Consensus: US Guidance Updates

Presenter: Eric Secemsky

November 06, 2021

Presentation TCT 2021

Leading with Evidence: Latest Data on Renal Denervation

Presenter: NULL

November 06, 2021

Presentation TCT 2021

Cardiac Neuromodulation Therapy Effect on Systolic Blood Pressure and Pulse Pressure in Patients with Isolated Systolic Hypertension In A Randomized Double-Blind Study Together With Long Term Follow Up Results (Backbeat Medical)

Presenter: Daniel Burkhoff

November 05, 2021

Presentation TCT 2021

Latest Evidence in the SPYRAL-HTN Clinical Program

Presenter: NULL

November 05, 2021

Presentation TCT 2021

Adequacy of Blood Pressure Control in High-Risk Hypertensive Patients: The DEGREE Study

Presenter: Victor Zeijen

November 04, 2021

Presentation TCT 2021

Cardiac Neuromodulation Therapy reduces Systolic Blood Pressure and Pulse Pressure in Patients With Isolated Systolic Hypertension in a Randomized Double-Blind Study

Presenter: Daniel Burkhoff

November 04, 2021

Presentation TCT 2021

Best Practices for the Future Implementation of Interventional Therapies for Hypertension

Presenter: Michael Bloch

November 04, 2021

Presentation TCT 2021

Debate: My Patient has a Blood Pressure of 150/90 Despite 2 Maximally Dosed Medications – Time for a Third Medication!

Presenter: Herbert D. Aronow

November 04, 2021

Advertisement

Lifetime Management, Durability and Clinical Relevance to Patients

Dietary and Lifestyle Approaches to Hypertension Management: What’s New and What’s Changed

Have We Gotten to the Final Word on Paclitaxel Safety?

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

Primordial Prevention Before End-stage CVD: Experts Call for a Fresh Focus

New Faces, New Formats, New Tech: What to Expect From TCT 2022

Mortality High in Patients With STEMI, COVID-19 on Hemodynamic Support

Debating ISCHEMIA: Do the Results Apply to CABG, Too?

Conservative Management, Careful Diagnosis Key for Good SCAD Outcomes

TARGET AC 4-year Results & Deep Dive in Diabetes Subgroup

GUIDE-HF Hints That Hemodynamic-Guided Management Works in HFpEF

Establishing Consensus: US Guidance Updates

Leading with Evidence: Latest Data on Renal Denervation

Cardiac Neuromodulation Therapy Effect on Systolic Blood Pressure and Pulse Pressure in Patients with Isolated Systolic Hypertension In A Randomized Double-Blind Study Together With Long Term Follow Up Results (Backbeat Medical)

Latest Evidence in the SPYRAL-HTN Clinical Program

Adequacy of Blood Pressure Control in High-Risk Hypertensive Patients: The DEGREE Study

Cardiac Neuromodulation Therapy reduces Systolic Blood Pressure and Pulse Pressure in Patients With Isolated Systolic Hypertension in a Randomized Double-Blind Study

Best Practices for the Future Implementation of Interventional Therapies for Hypertension

Debate: My Patient has a Blood Pressure of 150/90 Despite 2 Maximally Dosed Medications – Time for a Third Medication!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content